Choose a folder
Activities at the 52nd EASD Annual Meeting
The DISCOVER study was in the spotlight again at the 52nd European Association for the Study of Diabetes (EASD) Annual Meeting, 12–16 September 2016, Munich, Germany, with a poster presentation at the scientific congress and two DISCOVER meetings involving the Scientific Committee.
Professor Antonio Nicolucci from the Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy presented a poster on behalf of the DISCOVER Scientific Committee and his co-authors at the congress on Wednesday 14 September 2016. Their analysis – a retrospective assessment of electronic medical record data for 22 272 patients with type 2 diabetes in Canada, France, Germany and the UK – showed that after failure of first-line therapy, the most frequently prescribed treatments for type 2 diabetes were dipeptidyl peptidase-4 inhibitors and sulphonylureas, with or without metformin. However, 6 months after starting second-line therapy, many patients with type 2 diabetes included in the study had still not achieved target glycated haemoglobin (HbA1c) levels of 7% or less as recommended in clinical guidelines; observed reductions in HbA1c levels were similar for all second-line therapies.
As well as presenting results from the retrospective analysis at the congress, the Scientific Committee convened in Munich to discuss the data that are being generated by DISCOVER and develop a comprehensive publication plan. Study recruitment has been completed and availability of baseline data is imminent, so careful scheduling of educational activities relating to the DISCOVER results is a priority.
Professor Kamlesh Khunti from the University of Leicester, UK represented the Scientific Committee in Munich by chairing an important meeting of the European DISCOVER investigators. Professor Khunti updated the investigators on the study status before offering an informal platform for them to provide feedback on DISCOVER. In particular, the investigators were asked to share information about how their clinical teams are motivating patients to complete the study. The Scientific Committee engaged with the European investigators to identify the key findings of DISCOVER and prioritize their dissemination during this busy period in the scientific calendar.